FGEN
FibroGen, Inc.
Healthcare
$9.50
as of 8 Jan 2026, 18% below its 52-week high
Prices for FGEN have not updated since 8 Jan 2026. The listing may be suspended or delisted, so treat the figures on this page as out of date.
It has no dividend-growth score yet, and its cut-risk signals are low.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- No dividend
- Cash cover
- No dividend
- Earnings cover
- No dividend
- 5y dividend growth
- No dividend
Quality
Below the size we score
Capacity to keep growing the dividend
Risk
0
LowSignals of dividend-cut pressure
Trim
28
LowHow extended the valuation looks
Why Risk is 0
Valuation against its own history
As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of FGEN’s past readings.
- P/E0.8×P55, neutral for this measure
- Yield0.0%P50, neutral for this measure
- Net debt / EBITDA2.88P99, poor for this measure
- ROIC-27.0%P68, neutral for this measure
Forecast your income with the FGEN dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.